News for BICX Stock

BioCorRx Reports Business Update for the Second Quarter of 2024 BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia BioCorRx Reports Business Update for 2023 BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President BioCorRx Reports Business Update for the Third Quarter of 2023 BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder BioCorRx Reports Business Update for the Second Quarter of 2023 BioCorRx Submits Fast Track Application to FDA for BICX104, an Implantable Biodegradable Naltrexone Pellet for The Treatment of Opioid Use Disorder BioCorRx Provides Business Update for the First Quarter of 2023 BioCorRx Provides Business Update for 2022 BioCorRx Announced Interim Positive Safety and Pharmacokinetic Results of Phase 1 Clinical Trial at 4th Annual NIH HEAL Initiative Investigator Meeting BioCorRx Attended 4th Annual NIH HEAL Initiative Investigator Meeting; Shares Update on BICX104 Data BioCorRx to Present at Sequire Biotechnology Conference on February 2nd BioCorRx Appoints Pharmaceutical & Finance Veteran Harsha Murthy to the Board of Directors BioCorRx Announces Completion of Treatment Phase of Study Subjects and Preliminary Safety Data from Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder BioCorRx Partners with Government Plus to Expand its Beat Addiction Recovery Program in the United States BioCorRx Board of Directors Approves Exploration of Potential Spin-Off of BioCorRx Pharmaceuticals, Inc. BioCorRx Provides Business Update for the Third Quarter of 2022 BioCorRx Completes Final Subject Enrollment in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder BioCorRx to Present at the H.C. Wainwright 24th Annual Global Investment Conference BioCorRx Provides Business Update for the Second Quarter of 2022 BioCorRx to Participate in the Benzinga All Access Event on July 15th BioCorRx Announces First Subject Dosed in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder BioCorRx Featured on LiveNOW from FOX BioCorRx to Present at the LD Micro Invitational XII on June 7th BioCorRx and 2B3D to Pilot First-of-its-Kind PTSD and Addiction Treatment Solutions for Veterans in Metaverse Setting BioCorRx Business Update for the First Quarter of 2022 BioCorRx Begins Recruitment for Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder BioCorRx to Present at the Planet MicroCap Showcase 2022 in Las Vegas on May 4th BioCorRx Announces Additional Award of Nearly $100,000 from NIDA for BICX104, its Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder BioCorRx Provides 2021 Year-End Business Update BioCorRx to Participate in Two Upcoming Conferences BioCorRx Announces IRB Approval to Begin Phase I Clinical Trial of BICX104, an Implantable Biodegradable Naltrexone Pellet for the Treatment of Opioid Use Disorder BioCorRx Announces Orange County Research Center as Clinical Trial Site for First-In-Human Clinical Trial of BICX104 BioCorRx to Present at the H.C. Wainwright BioConnect 2022 Conference BioCorRx Appoints Drug Delivery Expert Jie Shen, Ph.D., to Scientific Advisory Board BioCorRx to Participate in the Benzinga All Access Event on December 2nd BioCorRx Acquires Intellectual Property for Drug Delivery BioCorRx Provides Business Update for the Third Quarter of 2021 BioCorRx Files Patent Application with the Russian Patent Office (Rospatent) for Naltrexone Implant BioCorRx to Present at LD Micro Main Event on Tuesday, October 12th BioCorRx Files Patent Application with USPTO for Naltrexone Implant Recro and BioCorRx Expand Development and Manufacturing Relationship to Support BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder BioCorRx Announces Award of Approximately $3.5 Million NIDA Grant for the Clinical Trial of BICX104, its Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder BioCorRx Provides Business Update for the Second Quarter of 2021 BioCorRx Welcomes Four Experts to Expanded Scientific Advisory Board BioCorRx Provides Business Update for the First Quarter of 2021 BioCorRx Receives FDA Clearance of Investigational New Drug (IND) Application for BICX104, its Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder BioCorRx Announces Submission of IND Application to the FDA for BICX104, Implantable Naltrexone BioCorRx Provides 2020 Year-End Business Update BioCorRx Completes $2.25 Million Private Placement BioCorRx Appoints Finance Veteran Joseph J. Galligan to the Board of Directors BioCorRx Partners with Truusight Health to Integrate Recovery Program Into Self-Funded Health Plans